Immuneering Co. (NASDAQ:IMRX) Short Interest Down 12.9% in March

Immuneering Co. (NASDAQ:IMRX) saw a large drop in short interest in the month of March. As of March 15th, there was short interest totalling 1,420,000 shares, a drop of 12.9% from the February 28th total of 1,630,000 shares. Based on an average trading volume of 1,700,000 shares, the days-to-cover ratio is currently 0.8 days. Currently, 5.5% of the shares of the company are short sold.

Immuneering Stock Down 3.8 %

IMRX stock traded down $0.06 during trading hours on Thursday, hitting $1.50. The company’s stock had a trading volume of 46,150 shares, compared to its average volume of 2,353,985. The stock has a 50 day moving average price of $1.73 and a two-hundred day moving average price of $2.01. Immuneering has a 12 month low of $1.00 and a 12 month high of $3.83. The company has a market capitalization of $53.83 million, a PE ratio of -0.76 and a beta of -0.32.

Immuneering (NASDAQ:IMRX) last released its quarterly earnings data on Thursday, March 20th. The company reported ($0.58) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.16). Sell-side analysts expect that Immuneering will post -1.86 earnings per share for the current year.

Analysts Set New Price Targets

IMRX has been the subject of several research reports. Needham & Company LLC reaffirmed a “buy” rating and set a $12.00 price objective on shares of Immuneering in a report on Friday, March 21st. Chardan Capital reiterated a “buy” rating and set a $13.00 target price on shares of Immuneering in a research report on Monday, March 24th. Finally, Morgan Stanley cut Immuneering from an “equal weight” rating to an “underweight” rating in a report on Friday, December 13th.

Institutional Trading of Immuneering

A number of large investors have recently bought and sold shares of IMRX. HighTower Advisors LLC raised its position in Immuneering by 21.4% during the third quarter. HighTower Advisors LLC now owns 53,360 shares of the company’s stock worth $132,000 after acquiring an additional 9,400 shares in the last quarter. Southport Management L.L.C. lifted its holdings in Immuneering by 4.9% in the fourth quarter. Southport Management L.L.C. now owns 215,000 shares of the company’s stock valued at $473,000 after buying an additional 10,000 shares during the period. Two Sigma Investments LP increased its stake in shares of Immuneering by 25.0% in the 4th quarter. Two Sigma Investments LP now owns 50,557 shares of the company’s stock valued at $111,000 after acquiring an additional 10,126 shares in the last quarter. Tang Capital Management LLC acquired a new stake in Immuneering in the 4th quarter valued at $27,000. Finally, XTX Topco Ltd raised its position in Immuneering by 177.2% in the 4th quarter. XTX Topco Ltd now owns 32,650 shares of the company’s stock valued at $72,000 after buying an additional 20,871 shares during the last quarter. 67.65% of the stock is owned by institutional investors.

Immuneering Company Profile

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors.